Anthrax Lethal Toxin Paralyzes Neutrophil Actin‐Based Motility

Russell L. During(University of Florida), Frederick S. Southwick(Office of Infectious Diseases), Conrad P. Quinn(Centers for Disease Control and Prevention), Wěi Li(Shougang (China)), Binghua Hao(Office of Infectious Diseases), David S. Stephens(Emory University), Joyce M. Koenig(Saint Louis University)
The Journal of Infectious Diseases
August 5, 2005
10.1086/432516
Cited by 89

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
HIF-1α pathway: role, regulation and intervention for cancer therapy
|Acta Pharmaceutica Sinica B|2015|1.9k
Epidemic meningitis, meningococcaemia, and Neisseria meningitidis
|The Lancet|2007|977
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients
|Science Translational Medicine|2016|416